GENKYOTEX
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
GENKYOTEX
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2006-01-01
Address:
Geneva, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.genkyotex.com
Total Employee:
11+
Status:
Active
Contact:
141228801013
Email Addresses:
[email protected]
Total Funding:
87.15 M USD
Technology used in webpage:
SPF LetsEncrypt Domain Not Resolving Apache Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS DMARC Google Analytics Event Tracking FLoC Opt-Out
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-02-28 | Genticel | Genticel acquired by Genkyotex | N/A |
Investors List
VI Partners
VI Partners investment in Post-IPO Equity - Genkyotex
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Post-IPO Equity - Genkyotex
Neomed Management
Neomed Management investment in Post-IPO Equity - Genkyotex
Andera Partners
Andera Partners investment in Post-IPO Equity - Genkyotex
Eclosion SA
Eclosion SA investment in Post-IPO Equity - Genkyotex
BioMedPartners
BioMedPartners investment in Post-IPO Equity - Genkyotex
Edmond de Rothschild Private Equity
Edmond de Rothschild Private Equity investment in Post-IPO Equity - Genkyotex
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series C - Genkyotex
Andera Partners
Andera Partners investment in Series C - Genkyotex
MP Healthcare Venture Management
MP Healthcare Venture Management investment in Series C - Genkyotex
Official Site Inspections
http://www.genkyotex.com
- Host name: plo14-18.drugdesigntech.com
- IP address: 185.172.102.18
- Location: Geneva Switzerland
- Latitude: 46.1917
- Longitude: 6.1361
- Timezone: Europe/Zurich
- Postal: 1227
More informations about "Genkyotex"
Genkyotex - Crunchbase Company Profile & Funding
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with …See details»
Genkyotex Company Profile - Office Locations, Competitors ... - Craft
Genkyotex (also known as Calliditas Therapeutics France) is a company that develops drugs to block the NOX enzymes that produce oxygen radicals. The drugs allow the treatment of …See details»
GENKYOTEX, Financial Info, Board and Management, …
GENKYOTEX Return To Hit List Organization Number: FR0013399474 . Company; Insights; CONTACT INFORMATION Phone: +33 (0)5 ...See details»
Genkyotex S.A - LinkedIn
Genkyotex’s lead product candidate, setanaxib, is a first-in-class NOX inhibitor that targets NOX 1 and NOX 4, which are major drivers of fibrogenesis in multiple organs. In Q4 2021, Calliditas ...See details»
GenKyoTex - VentureRadar
" Genkyotex is the leading biopharmaceutical company developing NOX therapies. Its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple …See details»
Genkyotex Company Profile 2025: Valuation, Funding & Investors
Genkyotex General Information Description. Developer of small molecule therapeutics designed for the treatment of chronic diseases. The company engaged in the business of research, …See details»
Genkyotex - Products, Competitors, Financials, Employees, …
Genkyotex is a biopharmaceutical company focused on the development of NOX inhibitors for various medical applications. The company's main offerings include setanaxib, a therapeutic …See details»
Genkyotex S.A. (Euronext Paris + Brussels: GKTX)
Feb 28, 2017 Listed on the Euronext Paris and Euronext Brussels markets, Genkyotex is established in France and, via its GenKyoTex Suisse SA subsidiary, in Switzerland. A leader …See details»
Genkyotex Innovation SAS - life-sciences-europe.com
Jul 10, 2012 Genkyotex was founded in 2006 by scientists from Switzerland, the USA and Japan, with backing from Geneva incubator Eclosion. Leading global investors Edmond de …See details»
Genkyotex - Funding, Financials, Valuation & Investors - Crunchbase
Genkyotex is registered under the ticker EPA:GKTX . Genkyotex is funded by 10 investors. VI Partners and Vesalius Biocapital Partners are the most recent investors. Genkyotex has …See details»
Orphanet: GenKyoTex S.A.
GenKyoTex S.A. Chemin des Aulx 14. 1228 PLAN-LES-OUATES . SWITZERLAND. Phone 1: 0041 (0)22 794 44 57 Phone 2: 0041 (0)22 880 10 13 Contact email: [email protected]. …See details»
Genkyotex SA Company Profile & Data: stocks, market cap
Sep 1, 2021 Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines …See details»
Genkyotex - Portfolio Company Profile, Executives and Private …
Genkyotex is a developer of selective NOX inhibitors. See Genkyotex's complete profile, including its private equity owner and the number of its executive contacts in our database. Genkyotex …See details»
Governance GenKyoTex SA Euronext Paris - MarketScreener.com
Feb 27, 2017 GenKyoTex SA is a France-based company involved in the biotechnology sector. The Company focuses on the development of therapies based on selective inhibition of …See details»
GenKyoTex S.A. - Venturelab
Jan 2, 2006 www.genkyotex.com Sectors. Biotech Biotech. Social links. linkedIn; twitter; website; Awards. TOP 100 Swiss Startups 2011 IMD 2008 Startup Competition CTI Start-up …See details»
Organization: GenKyoTex LEI 969500O5EBFI0TMRJM30
GenKyoTex. Information about the issuer. News and credit ratings. (LEI 969500O5EBFI0TMRJM30). Tables with accounting and financial reporting.See details»
Genkyotex SA - insights.citeline.com
Genkyotex SA, named after Geneva, Kyoto and Texas, the locations of three of the academic founders, is developing small molecules that specifically inhibit NOX enzymes. Its lead product …See details»
Genkyotex - Contacts, Employees, Board Members, Advisors
Organization. Genkyotex . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of Board …See details»
Genkyotex Company Information - Funding, Investors, and More
Track over 23,965 companies. Discover Fast-growing Global startups. Seedtable uses technology and people to track over 23,965 companies to help you find the right ones to partner with.See details»
Genkyotex - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Genkyotex uses 9 technology products and services including HTML5, Google Analytics, and Microsoft Outlook, according to G2 Stack. Genkyotex is actively using 5 technologies for its …See details»